Observational studyNephrology (Carlton, Vic.)2025
Potential Association Between Darbepoetin Alfa Administration and Reduced Proteinuria in Real-World Clinical Practice: A Post Hoc Analysis of the BRIGHTEN Study.
Observational study in Nephrology (Carlton, Vic.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potential Association Between Darbepoetin Alfa Administration and Reduced Proteinuria in Real-World Clinical Practice: A Post Hoc Analysis of the BRIGHTEN Study.Nephrology (Carlton, Vic.) · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimErythropoiesis-stimulating agents (ESAs) may be associated with inhibition of urinary protein; however, information from large-scale real-world clinical settings is insufficient. We aimed to investigate whether darbepoetin alfa (DA) was associated with reduced proteinuria in patients with chronic kidney disease (CKD) using data from the 'oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN)' observational study.
methodsIn total, 1161 patients treated with DA were analysed, including 307 with diabetic kidney disease (DKD), 286 with nephrosclerosis and 285 with chronic glomerulonephritis. We estimated the nonlinear relationship between DA dose and change in urinary protein-creatinine ratio (UPCR) at 12 weeks using a spline curve. We also explored the potential clinical relevance of the association between higher DA doses and changes in proteinuria by comparing the slope of DA dosage and UPCR reduction between patients with high and low ESA resistance, which is associated with CKD prognosis.
resultsThe UPCR appeared to decrease as the DA dose exceeded 50 μg, particularly in the DKD group. The slopes of DA dosage and UPCR reduction significantly differed (p = 0.009) between the high- and low-ESA resistance groups, especially in patients with DKD (p < 0.001). This difference was maintained after adjustment for factors such as the presence or absence of renin-angiotensin-aldosterone system inhibitors and blood pressure variability during the study period.
conclusionDA administration was associated with reduced proteinuria in a dose-dependent manner, particularly in patients with DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.